Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.

Lietz AP, Weaver DT, Melamed A, Rauh-Hain JA, Wright JD, Wright AA, Knudsen AB, Pandharipande PV.

PLoS One. 2019 Sep 20;14(9):e0222828. doi: 10.1371/journal.pone.0222828. eCollection 2019.

2.

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD.

Elife. 2019 Sep 3;8. pii: e47327. doi: 10.7554/eLife.47327.

3.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV.

J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.

PMID:
30785827
4.

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, Kelly VM, Shi W, Steelman L, Le N, Weaver DT, Lustgarten S, Wagner-Johnston ND, Zinzani PL.

J Clin Oncol. 2019 Apr 10;37(11):912-922. doi: 10.1200/JCO.18.00915. Epub 2019 Feb 11. Erratum in: J Clin Oncol. 2019 Jun 1;37(16):1448.

PMID:
30742566
5.

Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States.

Chen Q, Larochelle MR, Weaver DT, Lietz AP, Mueller PP, Mercaldo S, Wakeman SE, Freedberg KA, Raphel TJ, Knudsen AB, Pandharipande PV, Chhatwal J.

JAMA Netw Open. 2019 Feb 1;2(2):e187621. doi: 10.1001/jamanetworkopen.2018.7621.

6.

PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.

Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK.

Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17. No abstract available.

7.

Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach.

Weaver DT, Lietz AP, Mercaldo SF, Peters MLB, Hur C, Kong CY, Wolpin BM, Megibow AJ, Berland LL, Knudsen AB, Pandharipande PV.

AJR Am J Roentgenol. 2019 Mar;212(3):596-601. doi: 10.2214/AJR.18.20180. Epub 2019 Jan 8.

PMID:
30620679
8.

Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.

Criss SD, Weaver DT, Sheehan DF, Lee RJ, Pandharipande PV, Kong CY.

Urol Oncol. 2019 Mar;37(3):180.e11-180.e18. doi: 10.1016/j.urolonc.2018.11.016. Epub 2018 Dec 6.

PMID:
30528699
9.

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.

Blood. 2018 Dec 6;132(23):2446-2455. doi: 10.1182/blood-2018-05-850461. Epub 2018 Oct 4.

10.

Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model.

Peters MLB, Eckel A, Mueller PP, Tramontano AC, Weaver DT, Lietz A, Hur C, Kong CY, Pandharipande PV.

Pancreatology. 2018 Dec;18(8):928-934. doi: 10.1016/j.pan.2018.07.009. Epub 2018 Jul 29.

PMID:
30143405
11.

Current management of childhood ptosis.

Weaver DT.

Curr Opin Ophthalmol. 2018 Sep;29(5):395-400. doi: 10.1097/ICU.0000000000000508. Review.

PMID:
30096088
12.

Inactivation of deubiquitinase CYLD enhances therapeutic antibody production in Chinese hamster ovary cells.

Lu Y, Zhou Q, Han Q, Wu P, Zhang L, Zhu L, Weaver DT, Xu C, Zhang B.

Appl Microbiol Biotechnol. 2018 Jul;102(14):6081-6093. doi: 10.1007/s00253-018-9070-x. Epub 2018 May 15.

PMID:
29766242
13.

Pediatric Frontalis Suspension With Braided Polyester: A Comparison of Two Techniques.

Molinari A, Weaver DT, Goldblum TA, Silbert D, Lopez SP, Matta N.

J Pediatr Ophthalmol Strabismus. 2018 Jul 1;55(4):229-233. doi: 10.3928/01913913-20180213-02. Epub 2018 May 1.

PMID:
29709040
14.

Patient Navigation to Improve Cancer Screening in Underserved Populations: Reported Experiences, Opportunities, and Challenges.

Neal CD, Weaver DT, Raphel TJ, Lietz AP, Flores EJ, Percac-Lima S, Knudsen AB, Pandharipande PV.

J Am Coll Radiol. 2018 Nov;15(11):1565-1572. doi: 10.1016/j.jacr.2018.03.001. Epub 2018 Apr 21. Review.

PMID:
29685346
15.

Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.

Weaver DT, Raphel TJ, Melamed A, Rauh-Hain JA, Schorge JO, Knudsen AB, Pandharipande PV.

Gynecol Oncol. 2018 May;149(2):256-262. doi: 10.1016/j.ygyno.2018.02.007. Epub 2018 Mar 1.

PMID:
29486993
16.

Imaging Follow-up of Low-Risk Incidental Pancreas and Kidney Findings: Effects of Patient Age and Comorbidity on Projected Life Expectancy.

Raphel TJ, Weaver DT, Berland LL, Herts BR, Megibow AJ, Knudsen AB, Pandharipande PV.

Radiology. 2018 May;287(2):504-514. doi: 10.1148/radiol.2018171701. Epub 2018 Feb 5.

PMID:
29401040
17.

Management of a Case of Retinopathy of Prematurity With Poor Visualization of the Retina.

Bhatt A, Paul Chan RV, Weaver DT, Wagner RS.

J Pediatr Ophthalmol Strabismus. 2017 Sep 1;54(5):262-264. doi: 10.3928/01913913-20170613-01. No abstract available.

PMID:
28926661
18.

Inhibition of FAK kinase activity preferentially targets cancer stem cells.

Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha MS, Pachter JA, Weaver DT.

Oncotarget. 2017 Jun 16;8(31):51733-51747. doi: 10.18632/oncotarget.18517. eCollection 2017 Aug 1.

19.

The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.

Begum A, Ewachiw T, Jung C, Huang A, Norberg KJ, Marchionni L, McMillan R, Penchev V, Rajeshkumar NV, Maitra A, Wood L, Wang C, Wolfgang C, DeJesus-Acosta A, Laheru D, Shapiro IM, Padval M, Pachter JA, Weaver DT, Rasheed ZA, Matsui W.

PLoS One. 2017 Jul 10;12(7):e0180181. doi: 10.1371/journal.pone.0180181. eCollection 2017.

20.

Characterization of an Lrp/AsnC family regulator SCO3361, controlling actinorhodin production and morphological development in Streptomyces coelicolor.

Liu J, Li J, Dong H, Chen Y, Wang Y, Wu H, Li C, Weaver DT, Zhang L, Zhang B.

Appl Microbiol Biotechnol. 2017 Jul;101(14):5773-5783. doi: 10.1007/s00253-017-8339-9. Epub 2017 Jun 11.

PMID:
28601893
21.

Focal Adhesion Kinase as a Potential Target in AML and MDS.

Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M.

Mol Cancer Ther. 2017 Jun;16(6):1133-1144. doi: 10.1158/1535-7163.MCT-16-0719. Epub 2017 Mar 7.

22.

Engineering of an Lrp family regulator SACE_Lrp improves erythromycin production in Saccharopolyspora erythraea.

Liu J, Chen Y, Wang W, Ren M, Wu P, Wang Y, Li C, Zhang L, Wu H, Weaver DT, Zhang B.

Metab Eng. 2017 Jan;39:29-37. doi: 10.1016/j.ymben.2016.10.012. Epub 2016 Oct 26.

PMID:
27794466
23.

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG.

Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.

24.

Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.

Churchman ML, Evans K, Richmond J, Robbins A, Jones L, Shapiro IM, Pachter JA, Weaver DT, Houghton PJ, Smith MA, Lock RB, Mullighan CG.

JCI Insight. 2016;1(4). pii: 86082. doi: 10.1172/jci.insight.86082. Epub 2016 Apr 7.

25.

Inactivation of SACE_3446, a TetR family transcriptional regulator, stimulates erythromycin production in Saccharopolyspora erythraea.

Wu H, Wang Y, Yuan L, Mao Y, Wang W, Zhu L, Wu P, Fu C, Müller R, Weaver DT, Zhang L, Zhang B.

Synth Syst Biotechnol. 2016 Feb 16;1(1):39-46. doi: 10.1016/j.synbio.2016.01.004. eCollection 2016 Mar.

26.

Prevention of Lower Eyelid Retraction in a Case of Inferior Rectus Muscle Recession.

DeRespinis PA, Strominger MB, Weaver DT, Wagner RS.

J Pediatr Ophthalmol Strabismus. 2016 Jan-Feb;53(1):5-6. doi: 10.3928/01913913-20160112-01. No abstract available.

PMID:
26835992
27.

In vivo investigation to the macrolide-glycosylating enzyme pair DesVII/DesVIII in Saccharopolyspora erythraea.

Wu H, Li W, Xin C, Zhang C, Wang Y, Ren S, Ren M, Zhao W, Yuan L, Xu Z, Yuan H, Geng M, Zhang L, Weaver DT, Zhang B.

Appl Microbiol Biotechnol. 2016 Mar;100(5):2257-66. doi: 10.1007/s00253-015-7036-9. Epub 2015 Nov 10.

PMID:
26552796
28.

Surgical management of a case of congenital fourth nerve palsy.

Kipp MA, Koller HP, Weaver DT.

J Pediatr Ophthalmol Strabismus. 2015 Jan-Feb;52(1):6-8. doi: 10.3928/01913913-20141230-01. No abstract available.

PMID:
25643364
29.

c-Abl regulates proteasome abundance by controlling the ubiquitin-proteasomal degradation of PSMA7 subunit.

Li D, Dong Q, Tao Q, Gu J, Cui Y, Jiang X, Yuan J, Li W, Xu R, Jin Y, Li P, Weaver DT, Ma Q, Liu X, Cao C.

Cell Rep. 2015 Feb 3;10(4):484-96. doi: 10.1016/j.celrep.2014.12.044. Epub 2015 Jan 22.

30.

Capturing the target genes of BldD in Saccharopolyspora erythraea using improved genomic SELEX method.

Wu H, Mao Y, Chen M, Pan H, Huang X, Ren M, Wu H, Li J, Xu Z, Yuan H, Geng M, Weaver DT, Zhang L, Zhang B.

Appl Microbiol Biotechnol. 2015 Mar;99(6):2683-92. doi: 10.1007/s00253-014-6255-9. Epub 2014 Dec 31.

PMID:
25549616
31.

PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.

Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA, Xu Q.

Cancer Res. 2015 Jan 15;75(2):446-55. doi: 10.1158/0008-5472.CAN-14-1223. Epub 2014 Nov 28.

32.

Dissecting and engineering of the TetR family regulator SACE_7301 for enhanced erythromycin production in Saccharopolyspora erythraea.

Wu H, Chen M, Mao Y, Li W, Liu J, Huang X, Zhou Y, Ye BC, Zhang L, Weaver DT, Zhang B.

Microb Cell Fact. 2014 Nov 13;13:158. doi: 10.1186/s12934-014-0158-4.

33.

DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.

Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen EE, Stenson K, Weaver DT, Vokes EE.

PLoS One. 2014 Jul 14;9(7):e102112. doi: 10.1371/journal.pone.0102112. eCollection 2014.

34.

Use of telemedicine in retinopathy of prematurity.

Weaver DT.

Int Ophthalmol Clin. 2014 Summer;54(3):9-20. doi: 10.1097/IIO.0000000000000036. No abstract available.

PMID:
24879100
35.

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA.

Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639.

36.

SACE_3986, a TetR family transcriptional regulator, negatively controls erythromycin biosynthesis in Saccharopolyspora erythraea.

Wu P, Pan H, Zhang C, Wu H, Yuan L, Huang X, Zhou Y, Ye BC, Weaver DT, Zhang L, Zhang B.

J Ind Microbiol Biotechnol. 2014 Jul;41(7):1159-67. doi: 10.1007/s10295-014-1449-9. Epub 2014 May 3.

PMID:
24793123
37.

Telemedicine for retinopathy of prematurity.

Weaver DT.

Curr Opin Ophthalmol. 2013 Sep;24(5):425-31. doi: 10.1097/ICU.0b013e3283645b41. Review.

PMID:
23872819
38.

Management of a nasolacrimal duct fistula.

Guo S, Olitsky SE, Weaver DT.

J Pediatr Ophthalmol Strabismus. 2013 May-Jun;50(3):136-7. doi: 10.3928/01913913-20130419-01. No abstract available.

PMID:
23718936
39.

Review of thromboembolic prophylaxis in patients attending Cork University Hospital.

Byrne S, Weaver DT.

Int J Clin Pharm. 2013 Jun;35(3):439-46. doi: 10.1007/s11096-013-9760-5. Epub 2013 Mar 15.

PMID:
23494189
40.

Managing a case of hypotropia with a positive traction test.

Tien DR, Weaver DT.

J Pediatr Ophthalmol Strabismus. 2013 Jan-Feb;50(1):6-8. doi: 10.3928/01913913-20120720-01. No abstract available.

PMID:
23343087
41.

Telemedicine detection of type 1 ROP in a distant neonatal intensive care unit.

Weaver DT, Murdock TJ.

J AAPOS. 2012 Jun;16(3):229-33. doi: 10.1016/j.jaapos.2012.01.007.

PMID:
22681938
42.

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.

Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC.

Ann Oncol. 2012 Sep;23(9):2245-52. doi: 10.1093/annonc/mdr624. Epub 2012 Jan 23.

PMID:
22269178
43.

Preferred postoperative alignment in divergence excess intermittent exotropia.

Olitsky SE, Strominger MB, Weaver DT.

J Pediatr Ophthalmol Strabismus. 2012 Jan-Feb;49(1):5-7. doi: 10.3928/01913913-20110504-03. No abstract available.

PMID:
22268887
44.

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.

Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, Al-Adhami M, Villegas-Bergazzi V, Meyer JL, Kutok JL, Bartkova J, Bartek J, Nevanlinna H, Weaver DT, Blomqvist C.

Hum Pathol. 2012 Sep;43(9):1363-75. doi: 10.1016/j.humpath.2011.08.018. Epub 2011 Dec 26.

PMID:
22204715
45.

DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.

Alexander BM, Wang XZ, Niemierko A, Weaver DT, Mak RH, Roof KS, Fidias P, Wain J, Choi NC.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):164-71. doi: 10.1016/j.ijrobp.2011.05.033. Epub 2011 Oct 12.

PMID:
22000749
46.

The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Wang X, Weaver DT.

Am J Cancer Res. 2011;1(3):301-327. Epub 2010 Jan 3.

47.

XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.

Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D'Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR.

Clin Cancer Res. 2011 Aug 15;17(16):5513-22. doi: 10.1158/1078-0432.CCR-11-0086. Epub 2011 Jul 7.

48.

Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics.

Pierceall WE, Wolfe M, Suschak J, Chang H, Chen Y, Sprott KM, Kutok JL, Quan S, Weaver DT, Ward BE.

Anal Cell Pathol (Amst). 2011;34(3):159-68. doi: 10.3233/ACP-2011-014.

49.

DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer.

Alexander BM, Sprott K, Farrow DA, Wang X, D'Andrea AD, Schnitt SJ, Collins LC, Weaver DT, Garber JE.

Clin Cancer Res. 2010 Dec 1;16(23):5796-804. doi: 10.1158/1078-0432.CCR-10-0292.

50.

Treatment of a manifest strabismus with amblyopia.

Weaver DT, Burke MJ, Edmond JC.

J Pediatr Ophthalmol Strabismus. 2010 Jan-Feb;47(1):5-9. doi: 10.3928/01913913-20100106-01. No abstract available.

PMID:
20128545

Supplemental Content

Loading ...
Support Center